{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:54:28Z","timestamp":1793264068953,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[1998,11,1]],"date-time":"1998-11-01T00:00:00Z","timestamp":909878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prevention of allograft transplant rejection by the immunosuppressive 6-thiopurine drug azathioprine is limited by haematological toxicity (leucopenia or agranulocytosis). This toxicity is particularly apparent in subjects with low thiopurine methyltransferase activity (TPMTase) phenotype (1% in the Caucasian population). The thiopurine derivative 6-mercaptopurine is the active metabolite of azathioprine, and it would be of interest to measure, after validation of plasma measurements, the mean values of the pharmacokinetic parameters in transplant patients with high or intermediate TPMTase phenotypes (85 and 14% of the Caucasian population, respectively).<\/jats:p>\n               <jats:p>We measured erythrocyte TPMTase activity in 103 kidney transplant recipients of high or intermediate phenotype and calculated, after a test dose of azathioprine, the mean values of the pharmacokinetic parameters for 6-mercaptopurine. We also compared these values with the same parameters from one subject with low TPMTase activity phenotype. The mean observed area under the plasma concentration-time curve (AUC) was 190\u00b1140 ng mL\u22121 h and the elimination rate constant (el***) was 1.92\u00b11.<\/jats:p>\n               <jats:p>The pharmacokinetic parameters (AUC, Ke1, t.1\/2el (the elimination half-life)) of 6-mercaptopurine in transplant patients are normally distributed and suitable for acceptance as a gold standard value for this population of Caucasian transplant patients. It seems useful to calculate these parameters, representative of the systemic exposure of individual patients to the drug, before prescribing these subjects azathioprine immunosuppressive treatment. In subjects with low TPMTase phenotype these pharmacokinetic measurements could also be an index of dose reduction.<\/jats:p>","DOI":"10.1111\/j.2042-7158.1998.tb03343.x","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T15:02:43Z","timestamp":1302706963000},"page":"1261-1266","source":"Crossref","is-referenced-by-count":11,"title":["6-Mercaptopurine Pharmacokinetics After Use of Azathioprine in Renal Transplant Recipients with Intermediate or High Thiopurine Methyl Transferase Activity Phenotype"],"prefix":"10.1093","volume":"50","author":[{"given":"A","family":"Escousse","sequence":"first","affiliation":[{"name":"Biochimie Pharmacologique , C.H.U.-21033 Dijon Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Guedon","sequence":"additional","affiliation":[{"name":"Biochimie Pharmacologique , C.H.U.-21033 Dijon Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mounie","sequence":"additional","affiliation":[{"name":"Biochimie Pharmacologique , C.H.U.-21033 Dijon Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rifle","sequence":"additional","affiliation":[{"name":"N\u00e9phrologie , C.H.U.-21033 Dijon Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Mousson","sequence":"additional","affiliation":[{"name":"N\u00e9phrologie , C.H.U.-21033 Dijon Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"D\u2019Athis","sequence":"additional","affiliation":[{"name":"Informatique M\u00e9dicale , C.H.U.-21033 Dijon Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1998,11,1]]},"reference":[{"key":"2024103110022231100_cit1","first-page":"305","article-title":"A gas chromatographic method for measuring 6-mercaptopurine in serum","volume":"11","author":"Bailey","year":"1975","journal-title":"J. Chromatogr."},{"key":"2024103110022231100_cit2","first-page":"217","article-title":"Interactions of allopurinol with 6-mercaptopurine and azathioprine","volume":"36","author":"Brooks","year":"1982","journal-title":"Biomedicine"},{"key":"2024103110022231100_cit3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/j.1875-9114.1987.tb04046.x","article-title":"The therapeutic use of azathioprine in renal transplantation","volume":"7","author":"Chan","year":"1987","journal-title":"Pharmacotherapy"},{"key":"2024103110022231100_cit4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/j.1552-4604.1990.tb03606.x","article-title":"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients","volume":"30","author":"Chan","year":"1990","journal-title":"J. Clin. Pharmacol."},{"key":"2024103110022231100_cit5","first-page":"250","article-title":"Azathioprine (AZA) bioavailability and pharmacokinetics in kidney transplant patients","volume":"27","author":"Ding","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110022231100_cit6","first-page":"898","article-title":"Biochemistry and pharmacology of purine analogues","volume":"26","author":"Elion","year":"1967","journal-title":"Fed. Proc."},{"key":"2024103110022231100_cit7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2125.1991.tb03876.x","article-title":"A new sensitive graphical method for detecting deviations from the normal distribution of drug response: the NTV plot","volume":"32","author":"Endrenyi","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2024103110022231100_cit8","first-page":"309","article-title":"Azathioprine toxicity, 6-mercaptopurine bioavailability, and the \u2018poor\u2019 6-thiopurine methylator phenotype","volume":"48","author":"Escousse","year":"1995","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2024103110022231100_cit9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0003-2697(67)90311-9","article-title":"A fluorimetric method for the estimation of 6-mercaptopurine in serum","volume":"21","author":"Finkle","year":"1967","journal-title":"Ann. Biochem."},{"key":"2024103110022231100_cit10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1994.tb04314.x","article-title":"Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effects of drugs on inhibition","volume":"38","author":"Jacqz-Aigrain","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2024103110022231100_cit11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism","volume":"46","author":"Lennart","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110022231100_cit12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0140-6736(90)91745-V","article-title":"Genetic variations in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia","volume":"336","author":"Lennart","year":"1990","journal-title":"Lancet"},{"key":"2024103110022231100_cit13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00007890-198004000-00006","article-title":"Quantification of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients","volume":"29","author":"Lin","year":"1980","journal-title":"Transplantation"},{"key":"2024103110022231100_cit14","first-page":"20P","article-title":"Clinical pharmacological observation on azathioprine in kidney transplant patients","volume":"55","author":"Maddoks","year":"1978","journal-title":"Clin. Sci. Mol. Med."},{"key":"2024103110022231100_cit15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0192-0561(86)90067-6","article-title":"Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients","volume":"8","author":"Odlind","year":"1986","journal-title":"Int. J. Immunopharmacol."},{"key":"2024103110022231100_cit16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1399-0012.1993.tb00878.x","article-title":"Large inter-individual variability in bioavailability of azathioprine in renal transplant recipients","volume":"7","author":"Ohlman","year":"1993","journal-title":"Clin. Transplant."},{"key":"2024103110022231100_cit17","first-page":"820","article-title":"Azathioprine lymphotoxicity: potential lethal damage by its imidazole derivatives","volume":"38","author":"Sauer","year":"1988","journal-title":"Drug Res."},{"key":"2024103110022231100_cit18","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1172\/JCI103915","article-title":"The effect of 6-mercaptopurine on primary and secondary immune responses","volume":"38","author":"Schwartz","year":"1959","journal-title":"J. Clin. Invest."},{"key":"2024103110022231100_cit19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/clpt.1986.233","article-title":"Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia","volume":"40","author":"Suhl","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110022231100_cit20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/03602538508991433","article-title":"The pharmacology and metabolism of the thiopurine drugs: 6-mercaptopurine and azathioprine","volume":"16","author":"van Scoik","year":"1985","journal-title":"Drug Metab. Rev."},{"key":"2024103110022231100_cit21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0009-8981(78)90311-X","article-title":"Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties","volume":"85","author":"Weinshilboum","year":"1978","journal-title":"Clin. Chim. Acta"},{"key":"2024103110022231100_cit22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00007691-198507030-00015","article-title":"Analysis of 6-mercaptopurine in serum or plasma using high performance liquid chromatography","volume":"7","author":"Whalen","year":"1985","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.1998.tb03343.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/11\/1261\/60262003\/j.2042-7158.1998.tb03343.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/11\/1261\/60262003\/j.2042-7158.1998.tb03343.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:32:31Z","timestamp":1730370751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/50\/11\/1261\/6153108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11,1]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[1998,11,1]]},"published-print":{"date-parts":[[1998,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.1998.tb03343.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[1998,11]]},"published":{"date-parts":[[1998,11,1]]}}}